

OVERVIEW

- Focus on repurposing drugs for rare & infectious diseases
- Advancing clinical development of Bucillamine for infectious diseases, including COVID-19 (FDA Phase 3)
- Developing Psilocybin and Cannabidiol therapeutics for various CNS and inflammatory disorders
- Robust patent portfolio ([15 patents and patent applications](#))
- Awarded FDA Orphan Drug Status for CBD in the treatment of Autoimmune Hepatitis
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)
- Significantly undervalued compared to its peers

PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine	Infectious Diseases COVID-19	Phase 3 (COVID-19)	FDA approved for Phase 3
Psilocybin	Substance Use Disorder Methamphetamine	Phase 1	CTA with University of Wisconsin
Psilocybin	Neurological TBI (Concussion), Stroke	Pre-clinical	Target FDA Orphan Drug Approval
Psilocybin (Oral Formulations)	Mental Health Depression, Anxiety	Pre-clinical	Target FDA Approval
Cannabidiol CBD	Liver Diseases Autoimmune Hepatitis	Filing IND	Plan for Phase 2

STRATEGIC PARTNERS

<p>Infectious Diseases CRO</p>	<p>Psilocybin Oral Thin Film Delivery Collaboration</p>	<p>R&D partnership Psychedelic pharma</p>
<p>License of cannabidiol for treatment of Autoimmune Hepatitis</p>	<p>Psilocybin Biosynthesis Collaboration</p>	<p>Psilocybin Collaboration</p>

UPCOMING MILESTONES 2021

- Q3/Q4 FDA EUA Approval for Bucillamine in COVID-19**
- Q3** Complete enrollment of Phase 3 COVID-19 study
 - Q3** Submit FDA IND for Phase 2 study for CBD in AIH
 - Q3** Psilocybin oral thin film strip scale-up
 - Q3** Psilocybin research results in TBI (Concussion)
 - Q3** Phase 2 study - Psilocybin in Meth Disorder
 - Q3** FDA pre-IND for Psilocybin in TBI (Concussion)
 - Q4** FDA pre-IND for Psilocybin oral thin film strip
 - Q4** Initiate FDA Phase 2 for Psilocybin in TBI (Concussion)
 - Q4** Phase 2 clinical study for CBD in AIH

TEAM

Management

Michael Frank (Chairman & CEO)
Carmelo Marrelli (CFO)
Derrick Welch (Founder, Psilocin Pharma)


Scientific and Clinical

Dr. Kelly McKee (CSO)
Dr. Osnesmo Mpanju (Regulatory)
Dr. John Fahy, MD (Clinical and Scientific Advisor)
Dr. Joel Moody, MD (Medical and Clinical Advisor)

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

VALUATION COMPARISON



STOCK INFORMATION

Ticker:	CSE: RVV, OTC: RVVTF, FRANKFURT: 31R
Share Price:	\$0.53 (July, 2021)
52-week High / Low:	CAD \$0.92 / \$0.175
Shares Outstanding:	315,634,551
Market Cap:	CAD ~ \$167,000,000